医药前沿
醫藥前沿
의약전연
YIAYAO QIANYAN
2014年
6期
98-99
,共2页
食管癌%术前放化疗%局部晚期
食管癌%術前放化療%跼部晚期
식관암%술전방화료%국부만기
Esophagus Cancer%Preoperative Chemo radiotherapy%Local Advanced
目的：探研局部晚期食管癌术前放化疗的临床疗效。方法本院在2008年4月～2012年8月收治食管癌患者228例，随机分成两组，观察组118例采用术前放化疗再施行外科手术治疗，对照组110例直接施行外科手术。结果观察组107例患者肿瘤明显缩小，根治性切除101例，根治性切除率为85.6%；对照组根治性切除76例，根治性切除率为69.1%，观察组患者的根治性切除率高于对照组，两组比较差异具有统计学意义（P<0.05)。观察组姑息性切除率为9.3%，剖胸探查率8.5%；对照组姑息性切除率为14.6%，剖胸探查率18.2%，观察组的姑息性切除率、剖胸探查率低于对照组，两组比较差异具有统计学意义（P<0.05)。观察组患者术后3年生存率为63.6%，5年生存率为42.4%；对照组患者术后3年生存率35.5%，5年生存率为20.9%，观察组的3年生存率、5年生存率显著高于对照组，两组比较差异具有统计学意义（P<0.05)。结论术前放化疗可降低食管癌肿瘤分期，提高根治性切除率，不增加围术期并发症发生率，并且可提高患者术后生存率，值得临床推广应用。
目的：探研跼部晚期食管癌術前放化療的臨床療效。方法本院在2008年4月～2012年8月收治食管癌患者228例，隨機分成兩組，觀察組118例採用術前放化療再施行外科手術治療，對照組110例直接施行外科手術。結果觀察組107例患者腫瘤明顯縮小，根治性切除101例，根治性切除率為85.6%；對照組根治性切除76例，根治性切除率為69.1%，觀察組患者的根治性切除率高于對照組，兩組比較差異具有統計學意義（P<0.05)。觀察組姑息性切除率為9.3%，剖胸探查率8.5%；對照組姑息性切除率為14.6%，剖胸探查率18.2%，觀察組的姑息性切除率、剖胸探查率低于對照組，兩組比較差異具有統計學意義（P<0.05)。觀察組患者術後3年生存率為63.6%，5年生存率為42.4%；對照組患者術後3年生存率35.5%，5年生存率為20.9%，觀察組的3年生存率、5年生存率顯著高于對照組，兩組比較差異具有統計學意義（P<0.05)。結論術前放化療可降低食管癌腫瘤分期，提高根治性切除率，不增加圍術期併髮癥髮生率，併且可提高患者術後生存率，值得臨床推廣應用。
목적：탐연국부만기식관암술전방화료적림상료효。방법본원재2008년4월～2012년8월수치식관암환자228례，수궤분성량조，관찰조118례채용술전방화료재시행외과수술치료，대조조110례직접시행외과수술。결과관찰조107례환자종류명현축소，근치성절제101례，근치성절제솔위85.6%；대조조근치성절제76례，근치성절제솔위69.1%，관찰조환자적근치성절제솔고우대조조，량조비교차이구유통계학의의（P<0.05)。관찰조고식성절제솔위9.3%，부흉탐사솔8.5%；대조조고식성절제솔위14.6%，부흉탐사솔18.2%，관찰조적고식성절제솔、부흉탐사솔저우대조조，량조비교차이구유통계학의의（P<0.05)。관찰조환자술후3년생존솔위63.6%，5년생존솔위42.4%；대조조환자술후3년생존솔35.5%，5년생존솔위20.9%，관찰조적3년생존솔、5년생존솔현저고우대조조，량조비교차이구유통계학의의（P<0.05)。결론술전방화료가강저식관암종류분기，제고근치성절제솔，불증가위술기병발증발생솔，병차가제고환자술후생존솔，치득림상추엄응용。
Target: Research on clinical effects on local y advanced esophageal cancer of preoperative chemoradiotherapy. Methods: our hospital has cured 228 patients with esophageal cancer, randomly divided into two groups. 118 patients in observation group were performed surgery after preoperative chemoradiotherapy, while 110 patients in control group were performed surgery directly. Results: 107 patients in observation group have an obvious reduction in tumors. The radical resection rate of the observation group reaches 85.6% while of the control group is 69.1%, which shows a higher rate in the observation groups. The comparative differences of the two groups is of statistical significance(P<0.05).Pal iative resection rate in observation group is 9.3%, thoracotomy detection rate is 8.5% while pal iative resection rate in control group is 14.6%, thoracotomy detection rate is 20.9%. Both pal iative resection rate and thoracotomy detection rate in observation group is lower than in control group. The comparative differences of the two groups is of statistical significance(P<0.05). The 3 years survival rate of the patients in observation group after operation is 63.6%, and 5 years years survival rate is 42.4%. While the 3 years survival rate of the patients in control group after operation is 35.5% and 5 years years survival rate is 20.9%. Obviously, the survival rate of 3 years and 5 years after operation are both higher in observation group. The comparative differences of the two groups is of statistical significance(P<0.05).Conclusions: Preoperative chemoradiotherapy can reduce esophageal cancer staging and increase the radical resection rate without increasing occurrence rate of preoperative complications. What’s more, it can also increase the postoperative survival rate which is worthy of clinical popularization and application.
